Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):8-10. doi: 10.1007/s00259-018-4191-0. Epub 2018 Oct 11.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Glutamate Carboxypeptidase II*
  • Humans
  • Male
  • Prostatic Neoplasms*

Substances

  • Glutamate Carboxypeptidase II